Published in Leukemia on November 29, 2016
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer (2004) 3.58
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21
DNMT3A mutations in myeloproliferative neoplasms. Leukemia (2011) 1.95
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature (2015) 1.76
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res (2013) 1.61
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia (2010) 1.44
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol (2012) 1.36
A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia (2010) 1.27
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res (2014) 1.16
What are RBC-transfusion-dependence and -independence? Leuk Res (2010) 1.09
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res (2014) 0.87
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica (2015) 0.86
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol (2010) 0.80
Profile of pomalidomide and its potential in the treatment of myelofibrosis. Ther Clin Risk Manag (2015) 0.79
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia (2013) 0.91
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J (2016) 0.78
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. Leukemia (2016) 0.75
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia (2017) 0.75
Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. Bone Marrow Transplant (2016) 0.75
ICSH guidelines for the standardization of bone marrow immunohistochemistry. Int J Lab Hematol (2015) 0.75
The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia (2015) 0.75
GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia (2016) 0.75
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome. Bone Marrow Transplant (2017) 0.75
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J (2017) 0.75
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant (2017) 0.75
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia (2017) 0.75